Your trusted destination for CME, CPD & Medical Education across the Middle East.
The 5th Best of ESMO Egypt 2027 provides an educational platform for healthcare professionals to review important oncology developments and emerging clinical evidence. The meeting combines expert presentations and scientific discussions to help participants stay updated on advances in cancer management and apply relevant knowledge to clinical practice.
The 5th Best of ESMO Egypt 2027 is a specialized oncology meeting focused on highlighting important developments and clinical insights from the European Society for Medical Oncology (ESMO) community. The meeting brings together oncologists, hematologists, surgeons, radiologists, pathologists, and other healthcare professionals involved in cancer care. Scientific sessions are designed to explore significant advances in cancer diagnosis, treatment, targeted therapies, immunotherapy, and multidisciplinary management. Participants can gain insights into emerging evidence and key developments that can influence contemporary oncology practice. The event also provides a platform for specialists to discuss challenging cases, evolving treatment approaches, and practical applications of new clinical data. Expert-led presentations and scientific discussions encourage knowledge exchange among oncology professionals from Egypt and the wider region. By translating major oncology developments into clinically relevant discussions, the meeting supports continuous professional education and improved patient care.
Updates on adjuvant and neoadjuvant therapies for early-stage breast cancer.
Review of novel targeted treatments and immunotherapies for advanced disease.
Latest clinical trial data and treatment paradigms for colorectal malignancies.
Advances in the management of liver, biliary, and gastric cancers.
Practice-changing updates in non-small cell lung cancer targeted therapies.
Evaluating the evolving role of immune checkpoint inhibitors in thoracic malignancies.
Novel therapeutic approaches and sequencing in advanced prostate cancer.
Recent evidence and updated guidelines for kidney and bladder cancer management.
The impact of PARP inhibitors and maintenance therapies in ovarian cancer.
New systemic treatment options and clinical trial highlights.
| Emerging applications of antibody-drug conjugates across tumor types. |
| Advances in cellular and immune-based cancer treatment. |
| Biomarkers supporting diagnosis, prognosis and treatment selection. |
| Management of treatment toxicity, symptoms and survivorship. |
Secure your seat and earn full credit eligibility with encrypted checkout.
Secure payment processing & PCI-aligned flow